Summary
The response content provided does not align with the supplied FDA label excerpts for fetal toxicity/pregnancy. It focuses on weight gain/fluid overload and other general adverse effects without support from the provided fetal toxicity sections, and it omits key pregnancy/fetal harm warning and discontinuation instructions.
Category Scores
Accurate Statements
Unsupported Statements
Weight gain is not commonly listed as a typical side effect of losartan.
No support is provided in the supplied label excerpts (5.1, 8.1, 17) for whether weight gain is “not commonly listed” as an adverse effect.
Losartan is associated with dizziness.
No support is provided in the supplied fetal toxicity/pregnancy excerpts for dizziness as an associated adverse effect.
Losartan is associated with headache.
No support is provided in the supplied fetal toxicity/pregnancy excerpts for headache as an associated adverse effect.
Losartan is associated with low blood pressure.
While the pregnancy excerpt mentions hypotension as a potential fetal/neonatal adverse effect, the statement is not specifically tied to fetal/neonatal exposure and is not supported as a general association from the provided excerpts.
Losartan can be associated with kidney-related laboratory changes.
The provided excerpts mention reduced fetal renal function in utero, but the statement is general and not supported by the fetal toxicity/pregnancy excerpts.
Losartan can be associated with high potassium (hyperkalemia).
The pregnancy excerpt mentions neonatal hyperkalemia monitoring; however, the statement is presented generally for losartan and not limited to neonates with in utero exposure, so it is not supported as written by the supplied excerpts.
Losartan can be linked to fluid balance changes indirectly in some situations.
No support is provided in the supplied fetal toxicity/pregnancy excerpts for fluid balance changes as a losartan effect.
Changes in kidney function or potassium levels can change how the body manages fluids in some people.
This is explanatory/general physiologic linkage not supported by the provided fetal toxicity/pregnancy excerpts.
If fluid retention occurs, it can show up as swelling (edema) and a faster-than-usual weight increase.
Not supported by the supplied fetal toxicity/pregnancy excerpts.
Swelling in the legs/ankles, sudden weight gain over a short time, or shortness of breath can indicate fluid overload.
Not supported by the supplied fetal toxicity/pregnancy excerpts.
Seek prompt medical contact if weight increases quickly, especially if weight gain is accompanied by swelling, shortness of breath, or worsening fatigue.
Not supported by the supplied fetal toxicity/pregnancy excerpts.
Weight gain with losartan may indicate another condition such as heart, kidney, or fluid-management issues.
Not supported by the supplied fetal toxicity/pregnancy excerpts.
Common non-medication causes of weight gain after starting losartan include diet changes.
Not supported by the supplied fetal toxicity/pregnancy excerpts.
Common non-medication causes of weight gain after starting losartan include reduced activity.
Not supported by the supplied fetal toxicity/pregnancy excerpts.
Common non-medication causes of weight gain after starting losartan include other medications that may cause weight gain.
Not supported by the supplied fetal toxicity/pregnancy excerpts.
Progression of underlying conditions such as heart failure can cause weight gain.
Not supported by the supplied fetal toxicity/pregnancy excerpts.
The combination with other blood pressure medicines may matter.
No drug-interaction or specific pregnancy counseling details are provided in the supplied fetal toxicity/pregnancy excerpts.
Contradictions
Important Omissions
That losartan potassium and hydrochlorothiazide can cause fetal harm during pregnancy (especially 2nd/3rd trimesters), including reduced fetal renal function, oligohydramnios, fetal lung hypoplasia, skeletal deformities, hypotension, renal failure, and death; and that pregnancy should be detected and the drug discontinued as soon as possible.
Importance:
High
That thiazides (hydrochlorothiazide) cross the placenta and adverse reactions include fetal/neonatal jaundice and thrombocytopenia.
Importance:
Moderate
That neonates with in utero exposure should be closely observed for hypotension, oliguria, and hyperkalemia, and that exchange transfusions or dialysis may be required.
Importance:
High
Pregnancy counseling for female patients of childbearing age (report pregnancies promptly; discuss treatment options for women planning pregnancy).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The provided content does not cover the label’s fetal toxicity/pregnancy warnings and neonatal monitoring requirements, which are central to patient safety for pregnancy-related use. It instead offers unrelated claims about weight gain/fluid overload without label support from the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Response content omits key FDA-label fetal toxicity/pregnancy warnings and neonatal monitoring/discontinuation guidance, and includes multiple unsupported general adverse-effect statements not supported by the supplied label excerpts.
Suggested Improvement
Limit claims to the supplied label excerpts for fetal toxicity/pregnancy (5.1, 8.1, 17): disclose fetal harm during 2nd/3rd trimesters, instruct discontinuation when pregnancy is detected, mention hydrochlorothiazide placental crossing and fetal/neonatal jaundice/thrombocytopenia, and state neonatal monitoring for hypotension/oliguria/hyperkalemia with possible exchange transfusion/dialysis.